Miller V - Search Results

1

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.

Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W. Chmielecki J, et al. Among authors: miller v. J Thorac Oncol. 2012 Feb;7(2):434-42. doi: 10.1097/JTO.0b013e31823c5aee. J Thorac Oncol. 2012. PMID: 22173702 Free PMC article.

2

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.

Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA. Francis PA, et al. Among authors: miller va. Lung Cancer. 1995 Apr;12 Suppl 1:S163-72. doi: 10.1016/0169-5002(95)00432-z. Lung Cancer. 1995. PMID: 7551925 Free article. Review.

3

Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2).

Kris MG, Pisters KM, Ginsberg RJ, Rigas JR, Miller VA, Grant SC, Gralla RJ, Heelan RT, Martini N. Kris MG, et al. Among authors: miller va. Lung Cancer. 1995 Apr;12 Suppl 1:S47-57. doi: 10.1016/0169-5002(95)00420-6. Lung Cancer. 1995. PMID: 7551934 Free article. Review.

4

Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.

Miller VA, Rigas JR, Pisters KM, Grant SC, Pfister DG, Heelan RT, Kris MG. Miller VA, et al. Am J Clin Oncol. 1995 Aug;18(4):303-6. doi: 10.1097/00000421-199508000-00007. Am J Clin Oncol. 1995. PMID: 7625371 Clinical Trial.

5

New chemotherapeutic agents for non-small cell lung cancer.

Miller VA, Rigas JR, Grant SC, Pisters KM, Kris MG. Miller VA, et al. Chest. 1995 Jun;107(6 Suppl):306S-311S. doi: 10.1378/chest.107.6_supplement.306s. Chest. 1995. PMID: 7781411 Review.

6

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.

Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KM, Venkatraman ES, Woolley K, Heelan RT, Kris MG. Miller VA, et al. Cancer. 1995 Feb 15;75(4):968-72. doi: 10.1002/1097-0142(19950215)75:4<968::aid-cncr2820750411>3.0.co;2-y. Cancer. 1995. PMID: 7842417 Clinical Trial.

7

Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.

Rigas JR, Francis PA, Miller VA, Tong WP, Roistacher N, Kris MG, Orazem JP, Young CW, Warrell RP Jr. Rigas JR, et al. Among authors: miller va. Cancer Chemother Pharmacol. 1995;35(6):483-8. doi: 10.1007/BF00686832. Cancer Chemother Pharmacol. 1995. PMID: 7882456 Clinical Trial.

8

Modulation of all-trans retinoic acid pharmacokinetics by liarozole.

Miller VA, Rigas JR, Muindi JR, Tong WP, Venkatraman E, Kris MG, Warrell RP Jr. Miller VA, et al. Cancer Chemother Pharmacol. 1994;34(6):522-6. doi: 10.1007/BF00685665. Cancer Chemother Pharmacol. 1994. PMID: 7923564 Clinical Trial.

9

Metabolic phenotypes of retinoic acid and the risk of lung cancer.

Rigas JR, Miller VA, Zhang ZF, Klimstra DS, Tong WP, Kris MG, Warrell RP Jr. Rigas JR, et al. Among authors: miller va. Cancer Res. 1996 Jun 15;56(12):2692-6. Cancer Res. 1996. PMID: 8665495

10

Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP Jr. Miller VA, et al. J Clin Oncol. 1997 Feb;15(2):790-5. doi: 10.1200/JCO.1997.15.2.790. J Clin Oncol. 1997. PMID: 9053506 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,929 results

Search Page